Fig. 1. Receiver operating characteristic curves of Proclarix score for clinically significant prostate cancer, and decision curve analysis showing its net benefit in front of biopsying all men with suspected prostate cancer in the overall population (A, B), in men with serum prostate-specific antigen 2 to 10 ng/mL, prostate volume ≥35 mL, and normal digital rectal examination (Subset 1) (C, D), and men with serum prostate-specific antigen out of the interval 2 to 10 ng/mL, or prostate volume <35 mL, or abnormal digital rectal examination (Subset 2) (E, F). AUC: areas under the curve.